Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis) - Resistant mutants

John P. DeVincenzo; Caroline B. Hall; David W. Kimberlin; Pablo J. Sánchez; William J. Rodriguez; Barbara A. Jantausch; Lawrence Corey; Jeffrey Kahn; Janet A. Englund; JoAnn A. Suzich; Frances J. Palmer-Hill; Luis Branco; Syd Johnson; Nita K. Patel; Franco M. Piazza

doi:10.1086/423213

Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis) - Resistant mutants

John P. DeVincenzo, Caroline B. Hall, David W. Kimberlin, Pablo J. Sánchez, William J. Rodriguez, Barbara A. Jantausch, Lawrence Corey, Jeffrey Kahn, Janet A. Englund, JoAnn A. Suzich, Frances J. Palmer-Hill, Luis Branco, Syd Johnson, Nita K. Patel, Franco M. Piazza

Research output: Contribution to journal › Article › peer-review

56 Scopus citations

Abstract

Premature infants and those with chronic lung disease or congenital heart disease are at high risk of severe respiratory syncytial virus (RSV) disease. Palivizumab (Synagis), a humanized anti-RSV monoclonal antibody, has been used extensively since 1998 to prevent severe RSV disease in high-risk infants. To monitor for possible palivizumab-resistant mutants, an immunofluorescence binding assay that predicts palivizumab neutralization of RSV was developed. RSV isolates were collected at 8 US sites from 458 infants hospitalized for RSV disease (1998-2002). Palivizumab bound to all 371 RSV isolates able to be evaluated, including 25 from active-palivizumab recipients. The palivizumab epitope appears to be highly conserved, even in infants receiving prophylaxis with palivizumab.

Original language	English (US)
Pages (from-to)	975-978
Number of pages	4
Journal	Journal of Infectious Diseases
Volume	190
Issue number	5
DOIs	https://doi.org/10.1086/423213
State	Published - Sep 1 2004

ASJC Scopus subject areas

Immunology and Allergy
Infectious Diseases

Access to Document

10.1086/423213

Cite this

DeVincenzo, J. P., Hall, C. B., Kimberlin, D. W., Sánchez, P. J., Rodriguez, W. J., Jantausch, B. A., Corey, L., Kahn, J., Englund, J. A., Suzich, J. A., Palmer-Hill, F. J., Branco, L., Johnson, S., Patel, N. K., & Piazza, F. M. (2004). Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis) - Resistant mutants. Journal of Infectious Diseases, 190(5), 975-978. https://doi.org/10.1086/423213

DeVincenzo, JP, Hall, CB, Kimberlin, DW, Sánchez, PJ, Rodriguez, WJ, Jantausch, BA, Corey, L, Kahn, J, Englund, JA, Suzich, JA, Palmer-Hill, FJ, Branco, L, Johnson, S, Patel, NK & Piazza, FM 2004, 'Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis) - Resistant mutants', Journal of Infectious Diseases, vol. 190, no. 5, pp. 975-978. https://doi.org/10.1086/423213

@article{949783d160df47c3b26b842301c9cf4a,

title = "Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis) - Resistant mutants",

abstract = "Premature infants and those with chronic lung disease or congenital heart disease are at high risk of severe respiratory syncytial virus (RSV) disease. Palivizumab (Synagis), a humanized anti-RSV monoclonal antibody, has been used extensively since 1998 to prevent severe RSV disease in high-risk infants. To monitor for possible palivizumab-resistant mutants, an immunofluorescence binding assay that predicts palivizumab neutralization of RSV was developed. RSV isolates were collected at 8 US sites from 458 infants hospitalized for RSV disease (1998-2002). Palivizumab bound to all 371 RSV isolates able to be evaluated, including 25 from active-palivizumab recipients. The palivizumab epitope appears to be highly conserved, even in infants receiving prophylaxis with palivizumab.",

author = "DeVincenzo, {John P.} and Hall, {Caroline B.} and Kimberlin, {David W.} and S{\'a}nchez, {Pablo J.} and Rodriguez, {William J.} and Jantausch, {Barbara A.} and Lawrence Corey and Jeffrey Kahn and Englund, {Janet A.} and Suzich, {JoAnn A.} and Palmer-Hill, {Frances J.} and Luis Branco and Syd Johnson and Patel, {Nita K.} and Piazza, {Franco M.}",

year = "2004",

month = sep,

day = "1",

doi = "10.1086/423213",

language = "English (US)",

volume = "190",

pages = "975--978",

journal = "The Journal of infectious diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "5",

}

TY - JOUR

T1 - Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis) - Resistant mutants

AU - DeVincenzo, John P.

AU - Hall, Caroline B.

AU - Kimberlin, David W.

AU - Sánchez, Pablo J.

AU - Rodriguez, William J.

AU - Jantausch, Barbara A.

AU - Corey, Lawrence

AU - Kahn, Jeffrey

AU - Englund, Janet A.

AU - Suzich, JoAnn A.

AU - Palmer-Hill, Frances J.

AU - Branco, Luis

AU - Johnson, Syd

AU - Patel, Nita K.

AU - Piazza, Franco M.

PY - 2004/9/1

Y1 - 2004/9/1

N2 - Premature infants and those with chronic lung disease or congenital heart disease are at high risk of severe respiratory syncytial virus (RSV) disease. Palivizumab (Synagis), a humanized anti-RSV monoclonal antibody, has been used extensively since 1998 to prevent severe RSV disease in high-risk infants. To monitor for possible palivizumab-resistant mutants, an immunofluorescence binding assay that predicts palivizumab neutralization of RSV was developed. RSV isolates were collected at 8 US sites from 458 infants hospitalized for RSV disease (1998-2002). Palivizumab bound to all 371 RSV isolates able to be evaluated, including 25 from active-palivizumab recipients. The palivizumab epitope appears to be highly conserved, even in infants receiving prophylaxis with palivizumab.

AB - Premature infants and those with chronic lung disease or congenital heart disease are at high risk of severe respiratory syncytial virus (RSV) disease. Palivizumab (Synagis), a humanized anti-RSV monoclonal antibody, has been used extensively since 1998 to prevent severe RSV disease in high-risk infants. To monitor for possible palivizumab-resistant mutants, an immunofluorescence binding assay that predicts palivizumab neutralization of RSV was developed. RSV isolates were collected at 8 US sites from 458 infants hospitalized for RSV disease (1998-2002). Palivizumab bound to all 371 RSV isolates able to be evaluated, including 25 from active-palivizumab recipients. The palivizumab epitope appears to be highly conserved, even in infants receiving prophylaxis with palivizumab.

UR - http://www.scopus.com/inward/record.url?scp=4344651091&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4344651091&partnerID=8YFLogxK

U2 - 10.1086/423213

DO - 10.1086/423213

M3 - Article

C2 - 15295704

AN - SCOPUS:4344651091

SN - 0022-1899

VL - 190

SP - 975

EP - 978

JO - The Journal of infectious diseases

JF - The Journal of infectious diseases

IS - 5

ER -

Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis) - Resistant mutants

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this